Optiscan Imaging unveils high-tech imaging device for veterinarians
- Craig Nolan
- Jun 10
- 2 min read
Optiscan Imaging (ASX:OIL) has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment.
The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry.
The company’s InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses.
With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster.
Optiscan has partnered with the University of Minnesota’s College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options.
The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week.
“We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company’s life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.” Optiscan chief executive officer and managing director Camile Farah
Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Optiscan says its innovative device was designed specifically for animals and is suitable for use in a clinic or out in the field, due to its compact, durable and rugged design. Its ability to provide rapid insights is expected to help vets make quicker diagnostic and treatment decisions.
The company believes InSpecta has tremendous potential to expand its use across all categories of veterinary care, and emphasised the benefits it may deliver to the equine sector and overall animal care.
The company will now work to navigate the regulatory steps required for a commercial release, and will refine its commercial plans for the product during the rest of the year.
According to industry research house IBISWorld, the US veterinary services industry generated $67.6 billion (A$103.6B) in revenue in 2024 across veterinary care, pharmaceuticals and ancillary veterinary products. San Francisco-based Grand View Research, which estimated the US veterinary market was worth US$11.92B in 2022, tipped the industry would grow at an 8.7 per cent compound annual growth rate to 2030.
Given these numbers, Optiscan’s push into the lucrative veterinary industry may prove fruitful.
Is your ASX-listed company doing something interesting? Contact: office@bullsnbears.com.au
